AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 14.01 |
|---|---|
| Change | -0.300 2.141% |
| 52 W H/L (in USD) | 3.110/0.945 |
| EBITDA (in USD) | -95.748M |
| PE Ratio | -- |
| Volume | 118851 |
| Diluted Eps TTM | -1.83 |
| Total Assets (in USD) | 54.299M |
|---|---|
| Total Liabilities (in USD) | 25.368M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 46.674M |
| Market Cap (in USD) | 112.599 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Employees: 80
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A | Exec. Chairman | 1971 |
| 2. | Dr. Daniel Vitt | CEO, Pres & Director | 1968 |
| 3. | Mr. Glenn Whaley CPA | Chief Financial Officer | 1968 |
| 4. | Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer | 1964 |
| 5. | Dr. Hella Kohlhof | Chief Scientific Officer | 1973 |
| 6. | Jessica Breu | Head of Investor Relations & Communications | NA |
| 7. | Mr. Inderpal Singh | Gen. Counsel | 1966 |
| 8. | Mr. Patrick Walsh | Chief Bus. Officer | 1983 |
| 9. | Dr. Duane D. Nash J.D., M.B.A., M.D. | Executive Chairman | 1971 |
| 10. | Dr. Daniel Vitt Ph.D. | CEO, President & Director | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.370 0.842% | 44.03 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.001 0.003% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.710 0.602% | 452.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.250 0.041% | 615.18 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -120.407M | -92.945M | -44.017M | -34.933M | -41.475M |
| Minority Interest | - | - | - | - | - |
| Net Income | -154.296M | -92.794M | -43.959M | -34.826M | -41.475M |
| Selling General Administrative | 15.263M | 13.3M | 10.334M | 14.52M | 13.585M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.077M | 0.085M | 0.039M | 0.05M | 0.727M |
| Ebit | -119.488M | -91.75M | -48.971M | -37.032M | -34.796M |
| Ebitda | -53.548M | -91.665M | -48.932M | -36.982M | -34.069M |
| Depreciation And Amortization | 65.94M | 0.085M | 0.039M | 0.05M | 0.727M |
| Operating Income | -119.488M | -91.665M | -48.971M | -37.032M | -42.024M |
| Other Operating Expenses | 86.518M | 91.665M | 48.971M | 37.032M | 38.41M |
| Interest Expense | 1.041M | 0.085M | 0.058M | 0.107M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 1.041M | 0.066M | 0.058M | 0.107M | 0.521M |
| Net Interest Income | 1.041M | 0.066M | 0.058M | 0.107M | 0.521M |
| Income Tax Expense | 33.889M | -0.151M | -0.058M | -0.107M | 0.549M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 86.518M | 91.665M | 48.971M | 37.032M | 38.41M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | -0.919M | -1.28M | 4.954M | 2.099M | -3.586M |
| Net Income From Continuing Ops | -120.407M | -92.945M | -44.017M | -34.933M | -41.475M |
| Net Income Applicable To Common Shares | -120.407M | -92.945M | -44.017M | -34.933M | -41.475M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 54.299M | 127.753M | 139.1M | 167.861M | 65.955M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 5.157M | 9.49M | 18.125M | 1.234M | 2.861M |
| Total Liab | 25.368M | 14.069M | 11.985M | 9.076M | 7.592M |
| Total Stockholder Equity | 28.931M | 113.684M | 127.115M | 158.785M | 58.363M |
| Other Current Liab | 18.935M | 8.225M | 0.585M | 4.697M | 0.343M |
| Common Stock | 0.004M | 0.004M | 0.003M | 0.002M | 0.001M |
| Capital Stock | 0.004M | 0.004M | 0.003M | 0.002M | 0.001M |
| Retained Earnings | -410.892M | -317.28M | -196.873M | -103.928M | -59.911M |
| Good Will | - | 0M | 32.97M | 32.97M | 32.97M |
| Other Assets | - | 0.043M | 0.042M | 0.943M | 0.042M |
| Cash | 46.674M | 106.745M | 86.863M | 127.452M | 29.369M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 24.729M | 13.077M | 11.401M | 8.397M | 7.072M |
| Current Deferred Revenue | - | - | 6.663M | - | 1.008M |
| Net Debt | -45.34M | -105.182M | -86.279M | -126.773M | -28.849M |
| Short Term Debt | 0.695M | 0.571M | 0.408M | 0.534M | 3.298M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1.334M | 1.563M | 0.584M | 0.679M | 0.52M |
| Other Stockholder Equity | 436.06M | 427.925M | 324.237M | 266.823M | 53.691M |
| Property Plant Equipment | - | 0.294M | 1.1M | 0.203M | 0.08M |
| Total Current Assets | 52.534M | 125.864M | 104.988M | 133.745M | 32.23M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 9.629M | - | - | - |
| Net Receivables | 0.703M | 2.657M | 2.15M | 1.643M | 0.758M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -2.657M | -2.15M | 3.416M | - |
| Accounts Payable | 5.099M | 4.281M | 3.745M | 3.7M | 2.423M |
| Accumulated Other Comprehensive Income | 3.759M | 3.035M | -0.252M | -4.112M | -1.373M |
| Non Currrent Assets Other | - | 0.043M | 0.042M | 0.042M | 0.042M |
| Non Current Assets Total | 1.765M | 1.889M | 34.112M | 34.116M | 33.725M |
| Capital Lease Obligations | 1.334M | 1.563M | 0.584M | 0.679M | 0.52M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -9.741M | -0.067M | -0.146M | 10.536M | -0.415M |
| Total Cashflows From Investing Activities | -9.741M | -0.067M | -0.146M | 10.536M | -0.415M |
| Total Cash From Financing Activities | 95.76M | 42.841M | 144.431M | 34.895M | 0.004M |
| Net Income | -120.407M | -92.945M | -44.017M | -34.933M | -41.475M |
| Change In Cash | 19.882M | -40.589M | 98.083M | 16.297M | -43.577M |
| Begin Period Cash Flow | 86.863M | 127.452M | 29.369M | 13.072M | 56.901M |
| End Period Cash Flow | 106.745M | 86.863M | 127.452M | 29.369M | 13.324M |
| Total Cash From Operating Activities | -65.144M | -83.233M | -46.124M | -28.545M | -43.165M |
| Depreciation | 0.077M | 0.085M | 0.039M | 0.05M | 0.727M |
| Other Cashflows From Investing Activities | - | - | - | 10.591M | 0.182M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.182M | 0.092M | 144.431M | 34.895M | 0.004M |
| Other Cashflows From Financing Activities | 0.005M | -0.067M | -0.146M | -0.27M | -0.111M |
| Capital Expenditures | 0.112M | 0.067M | 0.146M | 0.055M | 0.597M |
| Change In Working Capital | 9.53M | -9.279M | -2.365M | -1.359M | -7.606M |
| Other Non Cash Items | 37.727M | 8.625M | -2.528M | 1.54M | 0.234M |
| Free Cash Flow | -65.256M | -83.3M | -46.27M | -28.6M | -43.762M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1893057 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1469129 |
| 3. | Fidelity Extended Market Index | 2 years ago | 530889 |
| 4. | BlackRock Extended Equity Market K | 2 years ago | 232915 |
| 5. | A4Investments SICAV SIF ACCI IlanaA2EURH | 2 years ago | 225000 |
| 6. | iShares Micro-Cap ETF | 2 years ago | 184965 |
| 7. | Fidelity Total Market Index | 2 years ago | 152108 |
| 8. | BlackRock Extended Mkt Composite | 2 years ago | 116402 |
| 9. | Bridgeway Ultra-Small Company Market | 2 years ago | 100000 |
| 10. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 98913 |
| 11. | Vanguard Balanced Index Inv | 2 years ago | 98039 |
| 12. | Fidelity Series Total Market Index | 2 years ago | 94720 |
| 13. | Northern Trust Extended Eq Market Idx | 2 years ago | 80747 |
| 14. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 80747 |
| 15. | Vanguard Instl Ttl Stck Mkt Idx Tr | 2 years ago | 69930 |
| 16. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 2 years ago | 69930 |
| 17. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 57009 |
| 18. | Fidelity Nasdaq Composite Index | 2 years ago | 56409 |
| 19. | Spartan Extended Market Index Pool E | 2 years ago | 37884 |
| 20. | Vanguard U.S. Eq Idx £ Acc | 2 years ago | 31867 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bvf Inc | 2 years ago | 8902972 |
| 2. | Avidity Partners Management LP | 2 years ago | 8902972 |
| 3. | HHG PLC | 2 years ago | 6993007 |
| 4. | Adage Capital Partners Gp LLC | 2 years ago | 5594406 |
| 5. | RTW INVESTMENTS, LLC | 2 years ago | 4567717 |
| 6. | Vanguard Group Inc | 2 years ago | 3394047 |
| 7. | Gratus Capital LLC | 2 years ago | 2052807 |
| 8. | Ikarian Capital, LLC | 2 years ago | 1612378 |
| 9. | 683 Capital Management LLC | 2 years ago | 699301 |
| 10. | Logos Global Management LP | 2 years ago | 421184 |
| 11. | Geode Capital Management, LLC | 2 years ago | 417613 |
| 12. | BlackRock Inc | 2 years ago | 362126 |
| 13. | Susquehanna International Group, LLP | 2 years ago | 334953 |
| 14. | COWEN AND COMPANY, LLC | 2 years ago | 317059 |
| 15. | Soleus Capital Management, L.P. | 2 years ago | 300000 |
| 16. | Two Sigma Investments LLC | 2 years ago | 254613 |
| 17. | Acadian Asset Management LLC | 2 years ago | 239962 |
| 18. | Two Sigma Advisers, LLC | 2 years ago | 173318 |
| 19. | UBS O'Connor LLC | 2 years ago | 167685 |
| 20. | Northern Trust Corp | 2 years ago | 164439 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...